ES2145004T3 - DERIVATIVES OF ANTIBODIES. - Google Patents

DERIVATIVES OF ANTIBODIES.

Info

Publication number
ES2145004T3
ES2145004T3 ES92810633T ES92810633T ES2145004T3 ES 2145004 T3 ES2145004 T3 ES 2145004T3 ES 92810633 T ES92810633 T ES 92810633T ES 92810633 T ES92810633 T ES 92810633T ES 2145004 T3 ES2145004 T3 ES 2145004T3
Authority
ES
Spain
Prior art keywords
antibodies
derivatives
cancer
hiv
infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92810633T
Other languages
Spanish (es)
Inventor
Mau Sung Co
Hans Loibner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919118013A external-priority patent/GB9118013D0/en
Priority claimed from GB929204514A external-priority patent/GB9204514D0/en
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2145004T3 publication Critical patent/ES2145004T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Human/mouse chimeric and humanized monoclonal antibodies recognizing the difucosyl Lewis blood group antigens Y-6 and B-7-2 are disclosed. They can be used in the treatment of cancer of epithelial origin, of small cell lung cancer and of HIV-infections, especially of AIDS.
ES92810633T 1991-08-21 1992-08-18 DERIVATIVES OF ANTIBODIES. Expired - Lifetime ES2145004T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919118013A GB9118013D0 (en) 1991-08-21 1991-08-21 Monoclonal antibodies and their use
GB929204514A GB9204514D0 (en) 1992-03-02 1992-03-02 Monoclonal antibodies and their use

Publications (1)

Publication Number Publication Date
ES2145004T3 true ES2145004T3 (en) 2000-07-01

Family

ID=26299429

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92810633T Expired - Lifetime ES2145004T3 (en) 1991-08-21 1992-08-18 DERIVATIVES OF ANTIBODIES.

Country Status (10)

Country Link
US (1) US5562903A (en)
EP (1) EP0528767B1 (en)
JP (1) JP3474592B2 (en)
AT (1) ATE188708T1 (en)
CA (1) CA2076432C (en)
DE (1) DE69230545T2 (en)
DK (1) DK0528767T3 (en)
ES (1) ES2145004T3 (en)
GR (1) GR3032944T3 (en)
PT (1) PT528767E (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ286547B6 (en) * 1992-05-22 2000-05-17 Novartis Ag Mouse monoclonal anti-idiotype antibodies, process of their preparation, pharmaceutical preparations in which they are comprised and their use
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
EP0781847A1 (en) * 1995-11-06 1997-07-02 MERCK PATENT GmbH Humanized monoclonal antibody
US6046310A (en) * 1996-03-13 2000-04-04 Protein Design Labs., Inc. FAS ligand fusion proteins and their uses
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
WO2000047625A2 (en) * 1999-02-12 2000-08-17 Genetics Institute, Inc. Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
AR022952A1 (en) 1999-03-19 2002-09-04 Smithkline Beecham Corp MONOCLONAL ANTIBODY OF ROEDOR SPECIFICALLY NEUTRALIZING FOR HUMAN INTERLEUQUINE-18, A FAB NEUTRALIZING FRAGMENT OR FRAGMENT F (AB ') 2, A COMPLEMENTARITY REGION OF IMMONOGLOBULIN LIGHT CHAIN (CDR), WHICH MAKES IT COMPRESSED , THE
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US20080063639A1 (en) * 2002-01-18 2008-03-13 Pierre Fabre Medicament Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
AT413486B (en) 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie USE OF AN ANTIBODY DIRECTED AGAINST LEWIS ANTIGENE
AT500648B1 (en) 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie SET FOR THE TREATMENT OF CANCER PATIENTS
AT413487B (en) 2002-08-12 2006-03-15 Igeneon Krebs Immuntherapie USE OF ANTIBODIES TO TUMOR ASSOCIATED ANTIGEN
US7780992B2 (en) * 2002-12-08 2010-08-24 Tareq Abduljalil Albahri Antiviral medicament
TW200539855A (en) * 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
WO2006005367A1 (en) * 2004-07-14 2006-01-19 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag N-glycosylated antibody
CA2589860A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
JP2008528668A (en) * 2005-02-03 2008-07-31 アンチトープ リミテッド Human antibodies and proteins
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
EP2027157B1 (en) 2006-05-25 2014-08-06 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
RU2461572C2 (en) 2006-06-07 2012-09-20 Биоэллаенс К.В. Antibodies recognising carbohydrate containing epitope on cd-43 and cea expressed on cancer cells, and methods of using such
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
US8497246B2 (en) * 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
AT504231A1 (en) 2006-10-03 2008-04-15 Hans Dr Loibner PREDICTIVE PARAMETERS
KR101546441B1 (en) * 2006-12-20 2015-08-24 엠엠알글로벌, 인코포레이티드 Antibodies and methods for making and using them
JP5901877B2 (en) 2007-07-27 2016-04-13 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． Methods and compositions for increasing [alpha] -L-iduronidase activity in the central nervous system
CN105732813A (en) 2007-12-18 2016-07-06 生物联合公司 Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
EP2261254A3 (en) 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
ES2544679T3 (en) * 2007-12-28 2015-09-02 Prothena Biosciences Limited Treatment and prophylaxis of amyloidosis
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
EP2894226B1 (en) * 2009-01-08 2021-04-14 Bio-Rad Laboratories, Inc. Methods and compositions for improving efficiency of nucleic acids amplification reactions
US9533055B2 (en) 2009-03-18 2017-01-03 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
ES2725200T3 (en) 2009-10-09 2019-09-20 Armagen Inc Methods and compositions to increase the activity of iduronate 2-sulfatase in the CNS
WO2011143624A2 (en) * 2010-05-14 2011-11-17 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
JP2012067106A (en) * 2011-10-14 2012-04-05 Greenovation Biotech Gmbh Glycosylated antibody
EP4338797A3 (en) 2011-12-02 2024-06-12 Armagen, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
UY36449A (en) 2014-12-19 2016-07-29 Novartis Ag COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
AU2017283787B2 (en) 2016-06-15 2020-09-17 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
CN109266656B (en) * 2018-10-10 2021-02-19 江苏集萃药康生物科技股份有限公司 Construction method and application of PD1 humanized BALB/c mouse model
GB201910899D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Binding members

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3751908T2 (en) * 1986-07-07 1997-02-06 Centocor Inc Murine-human chimeric immunoglobulin, specific for tumor-associated 17-1A antigen
US4971792A (en) * 1987-03-27 1990-11-20 The Wistar Institute Monoclonal antibodies against glycolipid antigens
US4978745A (en) * 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE4006308A1 (en) * 1990-02-28 1991-08-29 Sandoz Ag USE OF MONOCLONAL ANTIBODY BR 55.2 AGAINST SMALL CELLULAR LUNG CARCINOMA
DE4025499A1 (en) * 1990-08-11 1992-02-13 Sandoz Ag USE OF THE ANTIKOERPER BR55-2, DERIVATIVES, CONJUGATES AND FRAGMENTS FOR THE TREATMENT OF HIV INFECTIONS

Also Published As

Publication number Publication date
JPH05336989A (en) 1993-12-21
PT528767E (en) 2000-06-30
EP0528767B1 (en) 2000-01-12
US5562903A (en) 1996-10-08
GR3032944T3 (en) 2000-07-31
DK0528767T3 (en) 2000-04-17
CA2076432C (en) 2003-10-21
ATE188708T1 (en) 2000-01-15
JP3474592B2 (en) 2003-12-08
DE69230545D1 (en) 2000-02-17
EP0528767A1 (en) 1993-02-24
DE69230545T2 (en) 2000-07-06
CA2076432A1 (en) 1993-02-22

Similar Documents

Publication Publication Date Title
ES2145004T3 (en) DERIVATIVES OF ANTIBODIES.
ATE123652T1 (en) ANTIGENS.
DK69890A (en) MONOCLONAL ANTIBODIES REACTIVE WITH CACHETIN
EP0552296A4 (en) Mouse monoclonal antibodies
ES520692A0 (en) A PROCEDURE FOR THE PREPARATION OF IMMUNOENZYMATIC CONJUGATES.
DE3783277D1 (en) MONOCLONAL ANTIBODY AGAINST HUMAN LUNG CARCINOMA.
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
OA08485A (en) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas.
NO870476L (en) PROCEDURE FOR THE PREPARATION OF CROSS PROTECTIVE HUMAN MONOCLONAL ANTIBODY PREPARATIONS.
EP0198086A4 (en) Mouse human hybridoma producing antivirus human antibody, process for its preparation, and antivirus human monoclonal antibody.
EP0341684A3 (en) Human monoclonal antibody, hybridoma producing the same and pharmaceutical
DE3485712D1 (en) MONOCLONAL ANTIBODIES AGAINST HUMAN KIDNEY CANCER ANTIGENS AND METHOD.
AU584690B2 (en) E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma
FI885169L (en) Monoclonal antibody recognizing N-acetylneuraminic acid in the sequence, its use and hybridoma producing it
DE69129582D1 (en) ANTIBODIES AGAINST HUMAN PLASMIN-ALPHA 2-PLASMININHIBITOR COMPLEX, HYBRIDOMA AND IMMUNOASSAY
FI92716C (en) New monoclonal antibodies to IFN-Omega, their methods of preparation and their use for the purification and detection of IFN-Omega
DE69119591D1 (en) THE ANTIQUE DETECTED BY MCA-28A32
ATE137674T1 (en) ANTIGEN RECOGNIZED BY MCA 16-88
DE69232140D1 (en) THE PRODUCTION OF HUMAN, MONOCLONAL ANTIBODIES THAT ARE ACTIVE AGAINST HEPATITIS B SURFACE ANTIQUE
EP0334076A3 (en) Monoclonal antibody capable of recognizing an antigen associated with human arteriosclerosis, and process for preparing the same
NO924803L (en) TUMOR-RELATED MONOCLONAL ANTIBODY 88BV59
FI924818A7 (en) CDR-grafted anti-ICAM-1 antibodies suitable for human use, methods for their preparation and use
FI883765L (en) ANTIKROPPAR MOT BIOLOGISKT AKTIVA POLYPEPTIDER OCH DERAS ANVAENDNING VID DIAGNOSTISKA FOERFARANDEN.
AU2687992A (en) Sf-25 antibodies, especially chimeric antibodies, with specificity for the human tumor sf-25 antigen, methods for their production, and uses thereof
NO952506L (en) Antibody preparations for homogeneous minactivin and their use for the detection of minactivin in human body fluids

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 528767

Country of ref document: ES